✦ LIBER ✦

Modelling the Cost-Effectiveness of First-Line Biologics for Rheumatoid Arthritis in England and Wales

✍ Scribed by Righetti, C.; Lebmeier, M.; Pennington, B.; Brereton, N.J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Modelling the Cost-Effectiveness of Firs

✍ Righetti, C.; Lebmeier, M.; Pennington, B.; Brereton, N.J. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB

Effectiveness Of Second Line Biologic Us

✍ Schabert, V.F.; Yeaw, J.; Korn, J.; Quach, C.; Harrison, D.J.; Yun, H.; Joseph, 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

The Influence of HAQ Utility Mapping Alg

✍ Pennington, B. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

The cost-effectiveness of bevacizumab in

✍ P. Tappenden; R. Jones; S. Paisley; C. Carroll 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 194 KB

Effectiveness And Cost Per Responder Wit

✍ Curtis, J.; Chastek, B.; Becker, L.; Quach, C.; Harrison, D.J.; Yun, H.; Joseph, 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

Cost-effectiveness of adalimumab, etaner

✍ Soini, E. J.; Hallinen, T. A.; Puolakka, K.; Vihervaara, V.; Kauppi, M. J. 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 418 KB